These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24831275)

  • 1. Pharmacologic biomarkers in the development of stratified cancer medicine.
    Figg WD; Newell DR
    Clin Cancer Res; 2014 May; 20(10):2525-9. PubMed ID: 24831275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic biomarkers: falling short of the mark?
    Gainor JF; Longo DL; Chabner BA
    Clin Cancer Res; 2014 May; 20(10):2587-94. PubMed ID: 24831281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.
    Kinders R; Ferry-Galow K; Wang L; Srivastava AK; Ji JJ; Parchment RE
    Clin Cancer Res; 2014 May; 20(10):2578-86. PubMed ID: 24831280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies.
    Calvo E; Walko C; Dees EC; Valenzuela B
    Am Soc Clin Oncol Educ Book; 2016; 35():e175-84. PubMed ID: 27249721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker.
    Christie EL; Dawson SJ; Bowtell DD
    Cancer Res; 2016 Oct; 76(19):5590-5591. PubMed ID: 27698187
    [No Abstract]   [Full Text] [Related]  

  • 6. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
    Gingras I; Salgado R; Ignatiadis M
    Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translating metastasis-related biomarkers to the clinic--progress and pitfalls.
    Bidard FC; Pierga JY; Soria JC; Thiery JP
    Nat Rev Clin Oncol; 2013 Mar; 10(3):169-79. PubMed ID: 23381003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating DNA biomarkers: a primer for metastatic colorectal cancer?
    Eng C
    Lancet Oncol; 2015 Aug; 16(8):878-9. PubMed ID: 26184521
    [No Abstract]   [Full Text] [Related]  

  • 9. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of DNA Integrity, Applications for Cancer Research.
    Zonta E; Nizard P; Taly V
    Adv Clin Chem; 2015; 70():197-246. PubMed ID: 26231488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncology biomarkers--second annual GTCbio conference. Biomarkers for disease detection and therapeutics monitoring. 19-20 January 2009, Miami, FL, USA.
    Scholler N
    IDrugs; 2009 Apr; 12(4):207-10. PubMed ID: 19350459
    [No Abstract]   [Full Text] [Related]  

  • 12. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.
    Siravegna G; Bardelli A
    Mol Oncol; 2016 Mar; 10(3):475-80. PubMed ID: 26774880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers along the continuum of care in lung cancer.
    Holdenrieder S
    Scand J Clin Lab Invest Suppl; 2016; 245():S40-5. PubMed ID: 27542002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology.
    Hertz DL; McLeod HL
    Clin Cancer Res; 2014 May; 20(10):2530-40. PubMed ID: 24831276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells: a multifunctional biomarker.
    Yap TA; Lorente D; Omlin A; Olmos D; de Bono JS
    Clin Cancer Res; 2014 May; 20(10):2553-68. PubMed ID: 24831278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
    Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
    PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA as a liquid biopsy for cancer.
    Heitzer E; Ulz P; Geigl JB
    Clin Chem; 2015 Jan; 61(1):112-23. PubMed ID: 25388429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid Profiling of Circulating Nucleic Acids as a Novel Tool for the Management of Cancer Patients.
    Holdenrieder S
    Adv Exp Med Biol; 2016; 924():53-60. PubMed ID: 27753019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deceptive argumentation against diagnostic microdosing of anticancer drugs.
    Theile D; Mikus G
    Int J Cancer; 2014 Oct; 135(7):1753-4. PubMed ID: 24615734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.